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Recent data suggest that patients with a malignancy have a seven-fold increased risk for venous thromboembolism (VTE) compared
with those without cancer, suggesting that these patients may benefit from thromboprophylaxis. Mechanisms for the prevention of
thromboembolism can be divided into two broad categories: mechanical and pharmacological. Although generally used in
combination with pharmacotherapy, little evidence exists for the efficacy of mechanical modalities either in the broader population of
patients at risk for VTE or for patients with cancer specifically. A recent study using graduated compression stockings (GCS) for
thromboprophylaxis showed no support for the use of stockings in acute stroke patients. Established pharmacological modalities,
including warfarin, unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and the factor Xa inhibitor fondaparinux,
have been shown to reduce risk for VTE in general medical and surgical populations. In medical cancer patients, only limited data are
available for the efficacy of thromboprophylaxis. In contrast, considerable evidence indicates that thromboprophylaxis is warranted in
patients undergoing cancer surgery. The most recent evidence suggests that catheter-related thrombosis is not prevented by current
pharmacological modalities. On 22 May 2009, a group of clinicians based in the United Kingdom (UK) met in London, UK, to evaluate
recent data on cancer thrombosis. This article (the second of four) briefly reviews key data on the prevention of VTE in medical and
surgical oncology patients, providing context for a brief transcript of the surrounding discussion and a consensus statement,
developed by meeting attendees, on the implications of this information for UK clinical practice.
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It has been well known since the 19th century that patients with
cancer have an increased risk for venous thromboembolism (VTE)
compared with those without cancer. Recent investigations suggest
that, overall, patients with a malignancy have an approximately
seven-fold increased risk for first VTE compared with those
without cancer, with risk ranging from a low of 1.6-fold increased
risk in patients with head and neck cancers to a 28-fold increase in
patients with haematological malignancies (Heit et al, 2000; Blom
et al, 2005).
Clearly, the data summarised above indicate that the risk for
thromboembolism in patients with cancer is extremely high, and
show the need both for effective thromboprophylaxis to prevent an
initial event and adequate preventative efforts in patients who have
already had an event. Adequate thromboprophylaxis is particularly
important in light of the impact of thromboembolism on survival.
For example, among patients with colorectal cancer in the United
States, VTE was a significant predictor of death within 1 year of
cancer diagnosis among patients with local (hazard ratio 1.8) or
regional state disease (hazard ratio 1.5) (Alcalay et al, 2006).
Similarly, an analysis of a large registry of patients with cancer
(N¼235149) found that thromboembolism was a significant
predictor of decreased survival during the first year for all cancer
types, with hazard ratios ranging from 1.6 to 4.2 (Chew et al, 2006).
Despite the profound impact of VTE on survival, it is apparent
that there is a gap between recognition of VTE as an important
patient safety issue in patients with cancer and adequate treatment
(Kakkar et al, 2003). Risk assessment of VTE is not routinely
carried out in the United Kingdom. The FRONTLINE survey, a
comprehensive global survey of thrombosis and cancer, collected
data on the perceived risk and patterns of practice with regard to
VTE in cancer among patients undergoing surgical and medical
management of their malignancy. Responses from nearly 4000
health-care providers identified marked differences in the use of
thromboprophylaxis in surgical and medical patients. More than
50% of surgeons reported that they initiated thromboprophylaxis
routinely; in contrast, medical oncologists reported using throm-
boprophylaxis in less than 5% of medical patients (Kakkar et al,
2003). Notably, almost 20% of respondents worldwide reported
using aspirin for thromboprophylaxis, despite the lack of reliable
evidence for preventative use of this agent.
On 22 May 2009, a group of physicians and other health-care
providers based in the United Kingdom met in London, UK, to
examine the most recent data on cancer-associated thrombosis and
its implications for UK clinical practice. This article, which is the
second in a series of four covering broad topics in cancer
thrombosis, includes a summary of extant information on the
secondary prevention of VTE in patients with cancer, a discussion
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www.bjcancer.comon the relevance and relative importance of these data, and a
consensus statement developed by attendees on the implications of
this information for UK clinical practice.
OVERVIEW: MODALITIES FOR THE PRIMARY
PREVENTION OF VTE
Mechanisms for the prevention of thromboembolism can be
divided into two broad categories: mechanical and pharmaco-
logical. It should be noted that – throughout this discussion –
many modalities lack an evidence-based foundation for use in
patients with cancer specifically; in these cases, an effort has been
made either to select patients with cancer from the population, if
data are available, or to summarise other population data, with the
intention that the benefits and risks of these modalities are likely
to extend to the patient with malignancy.
Mechanical thromboprophylaxis
Early and frequent ambulation of patients at risk for VTE is an
important component of patient care. However, many patients
with cancer are immobilised long term; these patients are
candidates for mechanical thromboprophylaxis, generally used as
an adjunct to pharmacological therapy. A number of mechanical
thromboprophylactic modalities are available. They include
electrical calf stimulation, intermittent pneumatic compression
devices, graduated compression stockings (GCS), and venous foot
pump devices (Geerts et al, 2008). These modalities have in
common a relative lack of evidence from prospective, randomised,
controlled trials for their efficacy in any patient population and
have not been tested specifically in patients with cancer.
It is noteworthy that although patients with cancer are at
increased risk for VTE, they are also at increased risk for bleeding
(Prandoni et al, 2002). Although recognising their limitations, the
most important advantage of mechanical thromboprophylaxis is
the lack of bleeding potential – a significant concern in patients
with cancer. Despite the lack of an evidence base, these devices
represent an option for thromboprophylaxis, particularly in
patients at high risk for haemorrhagic complications, and as an
adjunct to medical thromboprophylaxis.
However, recent data from a randomised, controlled trial with
GCS or routine care and avoidance of GCS showed no support for
the use of thigh-length GCS in patients admitted to hospital, who
are immobile because of acute stroke, in the prevention of deep
vein thrombosis (DVT) (Dennis et al, 2009). Although it is not
clear how many of these patients were taking aspirin, a logical
extrapolation of these data is that immobile hospitalised patients
with cancer should not be offered GCS alone.
Pharmacological thromboprophylaxis
Aspirin Although effective in reducing major thrombotic
vascular events in patients with atherosclerotic disease, only
limited evidence suggests that aspirin provides protection against
VTE in hospitalised patients (Geerts et al, 2008). In general, aspirin
should not be used as a primary pharmacological modality for
thromboprophylaxis.
Warfarin The oral vitamin K antagonist warfarin is rapidly
absorbed and has a long half-life of 36–42h (Zacharski et al,
2005). Although effective as a thromboprophylactic modality, it
has a number of important issues that make its use challenging,
particularly in patients with cancer. In general, there is consider-
able inter-individual variation in response to warfarin, necessitat-
ing close monitoring to maintain the international normalised
ratio (INR) within a target range (generally 2.0–3.0) (Zacharski
et al, 2005). Diet, drug interactions, and other factors may change
the response to warfarin over time. Issues specific to patients with
cancer further complicate the use of warfarin in this population.
The relationship between INR level, thromboprophylactic efficacy,
and bleeding is not identical between patients with cancer and
those without cancer. In a retrospective analysis that included DVT
patients with and without malignancy who received vitamin K
antagonists for 3 months with a target INR of 2.0–3.0, patients
with malignancy had a clinically and significantly increased
incidence of recurrence (27.1/100 vs 9.0/100 patient-years) and
bleeding (13.3/100 vs 2.1/100 patient-years) compared with those
without cancer (Hutten et al, 2000). Therapeutic INRs are also
more difficult to sustain in patients with cancer, requiring more
frequent monitoring (Bona et al, 1995).
Unfractionated heparin Heparin consists of a mix of sulphated
mucopolysaccharides ranging from 3000 to 30000Da (mean
15000Da) in molecular weight (Hirsh et al, 2008). Only about
one-third of the heparin molecules possess the unique pentasac-
charide sequence responsible for the anticoagulant effect of
heparin. Heparin is administered by either continuous intravenous
infusion or by subcutaneous injection, generally in accordance
with published weight-based nomograms (Hirsh et al, 2008).
Although unfractionated heparin (UFH) has been shown to be
effective in the prevention of VTE (see below), it is subject to
important limitations. Heparin binds to a number of plasma
proteins, endothelial cells, and macrophages, which influence its
anticoagulant activity and contribute considerably to the varia-
bility of anticoagulant response observed in patients with VTE
(Hirsh et al, 2008). Moreover, the kinetics of heparin clearance are
complex, rendering the anticoagulant response to heparin non-
linear at therapeutic dosages. Equally important is the fact that
heparin has a propensity to induce immune-mediated platelet
activation, which can lead to heparin-induced thrombocytopenia
(HIT), and it has an effect on bone metabolism, which can result
in osteoporosis. Heparin has the advantage of rapid and complete
reversibility with protamine sulphate, a property that may be
useful in patients with cancer who, as a group, are at higher risk for
bleeding than those without cancer (Hirsh et al, 2008). Heparin has
a narrow therapeutic window; therefore, activated partial throm-
boplastin time must be monitored and the dosage adjusted
accordingly.
Low-molecular-weight heparins Low-molecular-weight heparins
(LMWHs) are derived by chemical or enzymatic depolymerisation
of UHF. In general, these agents have a mean molecular weight
of approximately 4000–5000Da (Hirsh et al, 2008). These low-
molecular-weight fragments have a reduced affinity for proteins
and cells, resulting in an improved anticoagulant and pharmaco-
kinetic profile compared with heparin, and a reduced propensity to
cause HIT and osteoporosis. In the United Kingdom, five LMWHs
are available for clinical use for specific indications, including
dalteparin, enoxaparin sodium, tinzaparin, nadroparin sodium,
and bemiparin. Dalteparin very recently gained a European licence
for use as a thromboprophylactic in patients with cancer. Low-
molecular-weight heparins are generally administered in once-
daily, fixed, or weight-adjusted doses. Regular monitoring is
generally not indicated, except in obese patients or in those with
renal insufficiency (Hirsh et al, 2008).
Fondaparinux Fondaparinux is a synthetic derivative of the
AT-binding pentasaccharide found in heparin and LMWH that
acts through AT-mediated selective inhibition of factor Xa. It is
administered at a fixed dose of 2.5mg for thromboprophylaxis
(Hirsh et al, 2008). In most cases, coagulation monitoring is not
needed in patients who receive fondaparinux.
Newer agents A number of newer agents have recently been made
available for clinical use or are in the late stages of clinical develop-
ment. None of these agents have been tested in patients with
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has been evaluated as a thromboprophylactic modality in patients
undergoing hip (Eriksson et al, 2007a) and knee (Eriksson et al,
2007b) surgery and has been shown to be at least as effective as
enoxaparin for the prevention of VTE in these high-risk patients.
Rivaroxaban, an oral, direct inhibitor of activated factor Xa, has
been shown to be superior to enoxaparin in the prevention of VTE
after total knee replacement (Lassen et al, 2008; Turpie et al, 2009)
and after total hip replacement (Eriksson et al, 2009). Apixaban,
another oral inhibitor of factor Xa, is currently in late-stage clinical
development (Shantsila and Lip, 2008; Jiang et al, 2009). Again, it
is important to emphasise that no data are yet available for these
newer agents in the cancer population, although US trials are
ongoing with apixaban in patients with cancer.
PRIMARY THROMBOPROPHYLAXIS IN MEDICAL
CANCER PATIENTS
Epidemiological studies have consistently shown that, overall,
medical cancer patients have at least a four-fold increased risk for
VTE; at the same time, they are at an elevated risk for bleeding
during anticoagulation (Prandoni et al, 2002). Moreover, VTE is
one of the most common and costly complications seen in patients
with cancer, and recurrence rates are high both after and during
anticoagulation. Careful weighing of the risks and benefits of
anticoagulation and meticulous attention to dosing are required to
successfully minimise the risks for both VTE and bleeding.
Few trials have specifically assessed the role of anticoagulants in
patients with cancer undergoing chemotherapy who did not have
another indication for anticoagulant therapy. In this study,
patients with metastatic breast cancer were randomised to treat-
ment with low-dose warfarin (adjusted to maintain the INR
between 1.3 and 1.9) or placebo, with treatment continuing until
1 week after the end of chemotherapy. Warfarin was associated
with a significant (P¼0.03) 83% relative reduction in the risk for
VTE from 4.4 to 0.7% without an increased risk for bleeding
(Levine et al, 1994). Two additional studies (TOPIC I and TOPIC
II), which to date have appeared in abstract form only, assessed
thromboprophylaxis in patients with metastatic breast cancer
and non-small-cell lung cancer (NSCLC), respectively. TOPIC I
enrolled patients with primary or secondary metastatic breast
carcinoma treated with chemotherapy; these patients were
randomly assigned to either LMWH certoparin or placebo for 6
months. In this study, the rate of VTE did not differ between the
certoparin group (4%) and the placebo group (4%), suggesting that
routine prophylaxis is not appropriate in this group. TOPIC II
enrolled patients with inoperable, disseminated NSCLC
undergoing chemotherapy; patients were randomised to either
certoparin or placebo for 6 months. In contrast to the TOPIC I
study, the incidence of VTE was reduced from 8.3% in placebo-
treated patients to 4.5% in the certoparin group. This risk
reduction was not significant because of considerable under-
powering of the study. Notably, risk for VTE correlated
with histological stage, with stage IV patients experiencing the
highest risk for an event and the greatest risk reduction with
LMWH prophylaxis. The Fragmin Advanced Malignancy Outcome
Study randomly assigned patients with advanced cancer to
dalteparin or placebo for up to 1 year; in this study, there was
no significant difference in the rates of symptomatic VTE between
the two groups overall. However, a post hoc analysis of this trial
found that survival improved with dalteparin among patients with
a better prognosis (defined as survival for 417 months). Caution
is warranted when interpreting these post hoc analyses (Kakkar
et al, 2004).
More evidence is available to support the routine use of
thromboprophylaxis in hospitalised general medical patients; this
information may be extrapolated to hospitalised cancer patients.
The MEDENOX study randomly assigned 1102 hospitalised acutely
ill medical patients to LMWH enoxaparin (40 or 20mg) or to
placebo for 6–14 days. The primary outcome (VTE detected by
bilateral venography or duplex ultrasonography between days
6 and 14 or documented PE) occurred in 5.5% of the enoxaparin
40mg group and in 14.9% of the placebo group (relative risk, 0.37;
Po0.001). Lower-dose enoxaparin did not reduce risk for VTE.
There was no difference between the two groups in the incidence of
adverse effects, including bleeding (Samama et al, 1999). Similarly,
the PREVENT study found that LMWH dalteparin was associated
with a 45% reduction in the relative risk of VTE in acutely ill
medical patients (P¼0.0015), without substantial differences in
the incidence of bleeding (Leizorovicz et al, 2005). Fondaparinux
was examined in a placebo-controlled study that enrolled a
population of 4800 acutely ill medical patients; in this study,
fondaparinux was associated with a 46.7% reduction in risk for
VTE (Cohen et al, 2006).
AMBULATORY PATIENTS
Approximately 61% of the 1587071 cancer patient hospital
episodes in the United Kingdom in 2007–2008 were ambulatory.
However, given that the average length of inpatient stay is 7 days
(median 3 days) (HES Online, http://www.hesonline.org.uk), the
duration of thromboprophylaxis may be extended to ‘‘ambulatory
patients’’ after discharge from the hospital. The publication of the
first large thromboprophylaxis randomised, controlled trial in
ambulatory cancer patients is imminent and may provide evidence
upon which to base extended prophylaxis in ambulatory patients.
Thromboprophylaxis is warranted with specific ambulatory
chemotherapy drug combinations that contain thalidomide and
lenalidomide. The risk for VTE in patients with multiple myeloma
receiving thalidomide has been found to range from 15 to 17% in
combination with dexamethasone (Cavo et al, 2002; Rajkumar
et al, 2006), and from 12 to 28% with thalidomide or lenalidomide
in combination with other chemotherapy agents, including
anthracyclines (Zangari et al, 2001; Bennett et al, 2006).
THROMBOPROPHYLAXIS IN CANCER SURGERY
Venous thromboembolism is common in all high-risk surgical
populations. Patients with cancer undergoing surgery have been
shown to have a two-fold or greater increased risk for fatal
pulmonary embolism (PE) compared with those without cancer
who are undergoing similar procedures (Geerts et al, 2008). Cancer
is also an independent predictor of thromboprophylaxis failure.
Considerable evidence is available for the efficacy of a broad
range of thromboprophylactic modalities in surgical patients. In
1988, Clagett and colleagues published a meta-analysis of low-dose
unfractionated heparin (LDUH) that examined the efficacy of this
modality in moderate- and high-risk general surgery patients. In
this analysis, 29 trials in which over 8000 surgical patients were
randomised to LDUH or control groups found the incidence of
DVT to be 8.7% among treated patients, compared with 25.2%
among controls (Po0.001) (Clagett and Reisch, 1998). Notably, the
overall incidence of major haemorrhage was identical in the LDUH
and control patients.
The efficacy of LMWHs in cancer surgical patients has been
assessed. A systematic review, published in 2007, pooled data from
26 randomised trials that included surgical oncology patients
(Leonardi et al, 2006). Overall, the rate of DVT was 12.7% among
patients who received pharmacological prophylaxis, compared
with 35.2% for controls. There was no difference between UFH and
LMWHs in efficacy, DVT location, or bleeding complications.
Notably, dosage of LMWH was critical: high-dose LMWH (defined
as 43400U daily) was significantly more effective than low-dose
treatment, lowering the rate of DVT from 14.5 to 7.9% (Po0.01)
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Bergqvist et al (2002) (Table 1).
Duration of prophylaxis with LMWHs after surgery for cancer
has been prospectively addressed. In a double-blind trial enrolling
patients undergoing planned curative surgery for abdominal or
pelvic cancer, patients received enoxaparin 40mg daily for 6–10
days and then were randomised to receive either enoxaparin or
placebo for another 21 days (Bergqvist et al, 2002). The primary
end point was the incidence of VTE between days 25 and 31. At the
end of the double-blind phase, the incidence of VTE was 4.8%
among patients randomised to enoxaparin, compared with 12.0%
among those who received placebo (P¼0.02); this difference
persisted at 3 months. The rate of bleeding was similar in the two
groups (Bergqvist et al, 2002) (Table 2).
The factor Xa inhibitor fondaparinux has not been prospectively
assessed in patients with cancer in a dedicated trial. However, its
efficacy was compared with that of dalteparin in a population of
patients undergoing high-risk abdominal surgery, of whom the
majority (approximately 56%) were undergoing colorectal surgery
(Agnelli et al, 2005). Among the 2048 patients who were evaluable
for efficacy, VTE occurred in 4.6% of fondaparinux patients and
6.1% of dalteparin patients (P¼0.144). Major bleeding was more
frequent among those who received fondaparinux (3.4%) compared
with those who received dalteparin (2.4%) (Agnelli et al, 2005).
PATIENTS WITH CENTRAL VENOUS CATHETERS
The presence of a central venous catheter (CVC) in patients with
cancer is known to predispose to upper-extremity DVT, resulting
in arm swelling, discomfort, PE, a predisposition to catheter-
related sepsis, and the potential for catheter replacement.
Several analyses have examined the impact of thromboprophy-
laxis on the rate of DVT in patients with CVCs. A 2007 meta-
analysis, conducted by Kirkpatrick et al (2007), found that
anticoagulant prophylaxis reduced the risk of all (combined
symptomatic and asymptomatic) catheter-associated DVT, with
relative risks by agent of 0.31 for LDUH, 0.37 for vitamin K
antagonists, and 0.72 for LMWH. Although provocative, later
analyses have not supported the conclusions of Kirkpatrick et al
(2007), a meta-analysis, published by Chaukiyal et al (2008),
included data from eight clinical trials enrolling a total of
1428 patients. There were no statistically significant differences
in the risk of catheter-related thrombosis for warfarin, heparin, or
LWMH vs placebo. No difference in the risk for bleeding between
active treatments and placebo was observed (Chaukiyal et al,
2008).
Most recently, the efficacy of warfarin in reducing catheter-
related thrombosis was prospectively examined in the open-label,
randomised WARP trial (Young et al, 2009). The UK study
randomly assigned nearly 1600 patients with cancer to no warfarin,
fixed-dose warfarin at a dosage of 1mg per day, or warfarin with
the dosage adjusted to maintain an INR of 1.5 and 2.0. No
difference in the rate of catheter-related thromboses was observed
between the no-warfarin and warfarin group (relative risk, 0.99;
P¼0.98) (Figure 1). When the warfarin group was divided into
those who received fixed-dose or adjusted-dose treatment, it was
found that dose-adjusted warfarin was superior to fixed-dose
warfarin in the prevention of catheter-related thromboses (3 vs 7%;
P¼0.002). Major bleeding was infrequent in any group. A meta-
analysis of warfarin intervention vs control showed no thrombo-
prophylactic advantage for warfarin (OR 0.75, CI 0.5–1.1; P¼0.1)
in 1356 cancer patients with CVCs (Young et al, 2009).
GUIDELINES FOR THROMBOPROPHYLAXIS IN
CANCER PATIENTS
Multiple – and often inconsistent – guidelines have been developed
in Europe and the United States to advise the use of thrombopro-
phylaxis in patients with cancer. They include those developed by
the European Society for Medical Oncology (ESMO), the American
Society of Clinical Oncology (ASCO), and the American College of
Chest Physicians (ACCP). This section will briefly review these
guidelines to set the stage for a discussion of their relative
applicability to UK general practice. Please refer to the complete
guidelines before considering practice changes.
ESMO guidelines
  LMWH (3400–5000U per day) or UFH (5000U three times
daily) is recommended in patients with cancer undergoing
major cancer surgery; patients undergoing elective major
abdominal or pelvic surgery should receive postdischarge
prophylaxis for up to 1 month after surgery.
  Among patients undergoing neurosurgery, routine prophylaxis
with LMWH is recommended.
  In medical patients, prophylaxis is recommended in hospita-
lised patients with cancer confined to bed with an acute medical
complication.
  Prophylaxis is not recommended for ambulatory cancer patients
receiving palliative chemotherapy for advanced disease, those
receiving adjuvant chemotherapy and/or hormone therapy, or
in patients with CVCs (Mandala ´ et al, 2008).
ASCO guidelines
  Hospitalised cancer patients should be considered as candidates
for VTE prophylaxis in the absence of bleeding or other
contraindications to anticoagulation.
Table 1 Frequency of DVT in a trial comparing high-dose (5000U) and
low-dose (2500U) dalteparin in the total study group and in the subgroup
with active malignancies (Bergqvist et al, 2002)
Dalteparin (2500U) Dalteparin (5000U) P-value
Total study group
ITT 12.7 6.6 o0.001
CP 13.1 6.8 o0.001
Patients with malignancy
ITT 14.9 8.5 o0.001
CP 15.1 8.8 0.001
Table 2 Extended-duration LMWH (4 weeks) provides superior
protection to short-term (1 week) therapy (Bergqvist et al, 2002)
Event
Short-term
enoxaparin
(N¼167)
Extended
duration
enoxaparin
(N¼165)
Risk
reduction
(95% CI) P-value
During double-blind period
All VTE 20 (12.0) 8 (4.8) 60 (10–82) 0.02
Proximal DVT 3 (1.8) 1 (0.6)
Distal DVT 17 (10.2) 7 (4.2)
PE 1 (0.6) 0
At 3 months
All VTE 23 (13.8) 9 (5.5) 60 (17–81) 0.01
Proximal DVT 4 (2.4) 2 (1.2)
Distal DVT 17 (10.2) 7 (4.2)
PE 2 (1.2) 0
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not recommended for ambulatory patients with cancer during
systemic chemotherapy, except in the case of patients receiving
thalidomide or lenalidomide with chemotherapy or dexametha-
sone. In these cases, LMWH or adjusted-dose warfarin is
recommended in patients with myeloma.
  All patients undergoing surgical intervention for malignant
disease should be considered for thromboprophylaxis, initiated
pre-operatively or as early as possible post-operatively,
generally with LDUH or LMWH unless contraindicated because
of active bleeding. Thromboprophylaxis should be continued
post-operatively for 7–10 days and up to 4 weeks in certain
patients. Mechanical methods may be added to pharmacother-
apy but should not be used as monotherapy (Lyman et al, 2007).
ACCP guidelines
  Routine thromboprophylaxis is recommended for patients with
cancer undergoing surgery. Specific modalities should be
consistent with the recommendations for surgical subtypes.
  Bedridden patients with cancer with an acute medical illness
should receive routine thromboprophylaxis, consistent with the
guidelines for all high-risk medical patients.
  Thromboprophylaxis is not recommended for patients with
cancer with indwelling CVCs.
  Routine thromboprophylaxis for the primary prevention of VTE
is not recommended for patients with cancer receiving
chemotherapy or hormonal therapy (Geerts et al, 2008).
DISCUSSION
Faculty: Are there biomarkers available for identifying high-risk
populations?
Ajay K Kakkar: We have been looking at isoforms of tissue
factor that have interesting properties. Total tissue factor does not
predict risk, however. In light of current data, a recommendation
to provide prophylaxis to all patients receiving chemotherapy is
not supported.
Faculty: It is difficult to know where the cutoff should be in
terms of providing thromboprophylaxis. While all the therapies
discussed today provide impressive risk reductions, the risk for an
event is quite low.
Ajay K Kakkar: In the context of cancer treatment, there has
been some discussion around the frequency of thromboembolic
events that the medical oncologist would consider sufficient to
justify primary prophylaxis. One figure that has been suggested is
in excess of 10%, with some suggesting that the rate would need to
be 15–20% to justify thromboprophylaxis. Trials in unselected
populations yield a frequency of approximately 4–5%. This
frequency is approximately as high as we see in other therapeutic
Log rank P=0.95
Log-rank P=0.002
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Figure 1 Time to catheter-related thrombosis in a population of patients randomised to warfarin (fixed or dose adjusted) or no warfarin. (A) No warfarin
vs warfarin; (B) fixed-dose warfarin vs dose-adjusted warfarin. Adapted with permission from Young et al (2009).
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week of prophylaxis in hospital results in a rate of symptomatic
VTE, 5 weeks after operation, of just under 4%. Extending
prophylaxis for 5 weeks reduces the rate to 1.3%. Most surgeons
would argue that is an important reduction.
Faculty: An analogy is the threshold for primary prophylaxis of
febrile neutropenia. The recommendations are to provide prophy-
laxis to patients at greater than 20% risk.
Faculty: The high threshold for prophylaxis of neutropenia is
driven, at least in part, by the cost of therapy. Prophylaxis for DVT,
even with LMWHs, is quite inexpensive.
Faculty: Perception also drives clinical practice. A recent
publication suggested that 25% of breast surgeons and oncologists
are not aware of the thromboembolic risks associated with cancer.
In qualitative studies with oncologists and palliative care
physicians, perception is that VTE is not a major problem.
Faculty: Part of the issue is the clinician’s individual experience.
Until recently, the primary option for thromboprophylaxis was
warfarin, and the burden and hazards of warfarin are often not
considered worthwhile. Today, we can give LMWH, but there is a
perception that we are burdening the patient with a daily self-
administered injection. In short, there are multiple factors driving
the decision to provide thromboprophylaxis that have little to do
with efficacy.
CONSENSUS STATEMENT
As venous thromboprophylaxis gains acceptance as a quality
measure that requires risk assessment in the UK health-care
system (National Institute for Health and Clinical Excellence,
2009), clinicians will be required to perform a risk assessment on
hospital admission, adhere to national guidelines for detection of
VTE (National Institute for Health and Clinical Excellence, 2010),
provide adequate thromboprophylaxis for all surgical oncology
patients and high-risk medical oncology patients, and monitor and
document thromboembolic outcomes for all patients with cancer,
including health economic outcomes.
Recent publications that have not supported the use of GCS as a
thromboprophylactic measure for acute stroke patients admitted
to hospital have thrown doubt on the value of GCS as a
thromboprophylactic modality, but this finding should not be
extended to all mechanical devices. It is clear, however, that GCS
should not be used as the only thromboprophylactic measure in
immobile medical patients.
Implementation of known thromboprophylaxis evidence is
difficult in the United Kingdom. The scale of the thrombosis and
malignancy challenge should be regularly highlighted to the UK
oncology community. Implementation of thromboprophylaxis in
patients with cancer may be hampered by several concerns that
warrant discussion at the hospital Trust level. These concerns
include fear of bleeding complications (particularly with warfarin)
and other side effects of medication (e.g., the risk for HIT
conferred by heparins). Evidence suggests that the risk for
bleeding among patients who receive pharmacological prophylaxis
is low among surgical oncology patients without significant
bleeding risk factors (Leonardi et al, 2006) and the risk for HIT
is o1% with LMWHs (Warkentin and Greinacher, 2004).
Every patient with malignancy should be regularly assessed for
risk of VTE as part of the standard procedure for hospital
attendance. The ‘Risk Assessment for Venous Thromboembolism’
tool, developed by the UK Chief Medical Officer’s Expert Advisory
Group (National Institute for Health and Clinical Excellence, 2009),
should be used as a minimum standard.
Additional appropriately powered clinical trials are required to
show the benefits and/or risks of mechanical, pharmacological, and
inferior vena caval filter thromboprophylaxis in the cancer popula-
tion. Pharmacological trials with new agents are best conducted in
patient populations with specific tumours, particularly in high-risk
tumour groups (e.g., pancreas, stomach, kidney, bladder, uterus, and
lung) (Chew et al, 2006) and in medical oncology patients. With the
shift of emphasis of care to the community, ambulatory and
hospitalised patients should be considered for clinical trials.
Patients with cancer are a particularly vulnerable group for
whom appropriate assessment and adequate thromboprophylaxis
are essential for those undergoing surgery. All other patients with
malignancy require regular assessment and appropriate treatment,
according to their risk of thrombosis. The forthcoming National
Institute for Health and Clinical Excellence final guidelines,
‘Prophylaxis of Venous Thromboembolism in Hospitalised Pa-
tients,’ in early 2010 (National Institute for Health and Clinical
Excellence, 2010) will provide a framework for improved quality
thromboprophylaxis care in the United Kingdom, implemented at
the hospital Trust level.
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